* A corporate client of Hybridan LLP.

** Potential means Intention to Float (ITF)  or similar announcement has been made.

***Arranged by type of listing and date of announcement.

****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication.

 


Dish of the Day

Admissions:  

The Smarter Web Company (SWC.L) announced it Admission to the Main Market after withdrawing from AQSE.

Delistings:  

None

 

What’s baking in the oven?

Market Movers:***

14 January: GlobalData (DATA.L), the data, insight, and technology Company expects to submit its application to move to the Main Market from AIM and to take place on 5 March.

 

 


Banquet Buffet****

 

Cadogan Energy Solutions  5.0p £11.9m (CAD.L)

The diversified energy Company announced that on January 30th it has successfully launched its new electricity production operations in Ukraine, with a first tranche of 4.6 MW. The remaining 7.7 MW of capacity is scheduled to be operational in the coming weeks. This achievement marks a significant milestone in Cadogan's strategy, shifting the business model to a multi-energy group and entering the power generation sector for the first time in the Company's history. The gas-to-power project and its gas infrastructure, which utilises the non-commercial gas from oil production, are fully complete and awaiting final approval to commence operations imminently.

Chesterfield Special Cylinders Holdings 54.0p £18.37m (CSC.L) 

The provider of bespoke, high-pressure gas containment solutions and services gave an update ahead of its AGM today. The update was on its defence orderbook which was strengthened in January with a strategically significant contract award from French prime contractor, Naval Group, for specialised pressure vessels on its Scorpène-class submarine programme. Within the first half of 2026, the Company expects further overseas defence contract awards for newbuild programmes and Integrity Management services.    A major contract award for large-scale hydrogen storage systems under the long-awaited UK government's first Hydrogen Allocation Round is also expected in the first half of 2026, driving further growth from this emerging sector from FY27.            

Earnz 5.75p £6.90m (EARN.L) 

The energy services Company whose objective is to capitalise on the drive for global decarbonisation reports increased activity following the recent Government announcement of their Warmer Homes Plan (WHP). There is increased order activity from the Social Housing Sector who are keen to access up to £15bn of spend to upgrade their housing stock, helping up to one million households out of fuel poverty by 2030. The scale of the plan is the largest ever public investment to upgrade British homes and cut bills reducing fuel poverty. The plan will cover the cost of solar panel installation, batteries, and heat pumps, and fund home upgrades for low-income and fuel poor households.

EnSilica 52.5p £49.85m (ENSI.L) 

The fabless chipmaker of mixed-signal ASICs (Application Specific Integrated Circuits) announced its unaudited results for the six months ended 30 November 2025. The Company recorded H1 FY26 revenues up 37% to £12.7m, while chip supply revenue increased 34% to £3.9m. The EBITDA profit was £1.7m and cash and cash equivalents on 30 November 2025 was £2.0m. With 95% of business already booked, the Board has confidence in achieving management expectations for FY26.

Hardide 21.0p £12.61m (HDD.L) 

Following on from the announcement on 1 December 2025, the provider of advanced surface coating technology today announced it has received an additional follow-on order worth $1.0m from the same customer. This order is expected for delivery in the second half of Hardide's financial year ending 30 September 2026. Accordingly, the Company now anticipates financial performance for FY26 to be ahead of previous expectations. During the course of FY26, the Company intends to begin a programme to upgrade infrastructure at its Martinsville plant to improve operational efficiency in meeting the significant uplift in demand in the North American region. The investment is expected to be funded by proceeds from this new order and the Group's existing resources.      

PCI-PAL 56.50p £39.49m (PCIP.L) 

The global cloud provider of secure payment solutions for business communications announced a trading update for the six months to 31 December 2025. The Group delivered a further record H1 for new business won, which together with increasingly efficient customer deployments, has contributed to a record real-term increase in ARR for a six month period. At the end of H1, ARR stood at £20.3m, a 21% increase year on year (25% on a constant currency basis), and CARR, the Company's leading indicator of future ARR, reached £24.0m, an increase of 18% year on year (21% on a constant currency basis). Revenue for the Period was £11.3m, while cash at period end was £2.6m.        

Portmeirion Group (PMP.L) 96.00p £13.67m 

The global homeware brands Group today issued a trading update in respect of its financial year ended 31st December 2025. Group Sales in FY 2025 are expected to be c.£91m, up 1% year-on-year at constant currency. Excluding the US market, impacted by tariffs, sales were up 8%. The Group has made proactive commercial changes in the US product offer and distribution, along with reduction of excess / end of line inventory, initial margin investment in accelerating the Made in Stoke-on-Trent onshoring initiative, as well as some upfront investment in future growth opportunities. As expected, the short-term impact of these measures when combined with the previously disclosed impact from the US import tariffs in what is the Group's largest and most profitable market, and significantly higher energy costs, National Insurance and minimum wage increases, will result in a headline loss before tax of c.£3.5m. The Group's net debt position was £17.5m at 31 December 2025 (FY24: net debt of £12.1m).      

Quantum Data Energy 3.61p £6.18m (MAST.L) 

The provider of Dynamic Electricity Generation capabilities and power supplies for datacentres announced, further to its RNS announcement dated 6 January 2026, that its 100% owned Pyebridge 8.1 MW flexible generation power asset has achieved another new record high electricity generation and revenues for any single calendar month to date in January 2026.  Pyebridge achieved electricity generation output and sales of c.1.8 Gigawatt/hours for January, while it generated and sold c.116 GWh of electricity during the 12-month rolling period up to January 2026 representing an increase of c.64% compared to the same prior year 12-month rolling period. Further, the Company’s third flexible generation power has progressed to financial close and into construction and commercial operations.

Shearwater Group 51.0p £11.2m (SWG.L) 

The cybersecurity, advisory and managed security services Group, announced that one of its companies, Brookcourt Solutions, has secured a c.£9m three-year contract renewal and expansion with a Global Financial Organisation. The contract win further supports the delivery of FY26 market expectations, with £2.7m to be recognised in FY26. Under the terms of the contract, Brookcourt has agreed a renewal of the customer's Advanced Email Gateway and Insider Threat Management arrangements, and expansion of the Secure Email Gateway capacity. Brookcourt Solutions will deliver, implement and support a complex, market-leading email security solution across the customer's global estate.

Trellus Health 0.73p £1.72m (TRLS.L) 

The healthcare Company provided a business update.  In October 2025, the Company entered into two 12-month contracts with global CROs (ICON plc and PIS Inc.) to support clinical trials for Takeda and Sanofi. The Company has also been granted preferred vendor status by both ICON plc and PSI Inc., which is expected to facilitate access to pharmaceutical sponsors and streamline future contracting processes. In addition, the Company continues to support an ongoing Phase 2 IBD clinical trial pursuant to its licensing agreement with AstraZeneca.  The Johnson & Johnson Health collaboration continues to progress and the agreement with Pfizer was renewed.  The Company expects revenue for FY 2025 to be c.$545k, while its monthly cash burn has been reduced to approximately $400k.


Status of this Note and Disclaimer

This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.

This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.

References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results.  Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.

In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.